Kenneth A Goldman sold $608k of WLTH
director at WEALTHFRONT CORP. 43,444 shares at an average of $14.00, traded Dec 11, 2025, filed Dec 15, 2025.
Score components
- +15RoleDirector
- +20Trade size$608k at market
- +20Share of holdings soldSold 54% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -26.5%, 3m -43.2%, 6m -36.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001218470-25-000012, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 11, 2025 | MOption exercise Common Stock | +6,945 | $0.00 | $0 | 6,945 | Dec 15, 2025 |
| Dec 11, 2025 | MOption exercise Common Stock | +27,778 | $0.00 | $0 | 34,723 | Dec 15, 2025 |
| Dec 11, 2025 | MOption exercise Common Stock | +30,500 | $0.00 | $0 | 65,223 | Dec 15, 2025 |
| Dec 11, 2025 | MOption exercise Common Stock | +15,496 | $0.00 | $0 | 80,719 | Dec 15, 2025 |
| Dec 11, 2025 | SOpen-market sale Common Stock | -38,071 | $14.00 | $533k | 42,648 | Dec 15, 2025 |
| Dec 11, 2025 | SOpen-market sale Common Stockindirect: By Goldman-Valeriote Family Trust | -5,373 | $14.00 | $75k | 0 | Dec 15, 2025 |
| Dec 15, 2025 | CConversion Common Stockindirect: By Goldman-Valeriote Family Trust | +53,732 | - | - | 48,359 | Dec 15, 2025 |
| Jul 17, 2025 | GGift Series C Preferred Stockderivativeindirect: By Goldman-Valeriote Family Trust | -25,000 | - | - | 53,732 | Dec 15, 2025 |
| Dec 11, 2025 | MOption exercise Restricted Stock Unitsderivative | -6,945 | $0.00 | $0 | 0 | Dec 15, 2025 |
| Dec 11, 2025 | MOption exercise Restricted Stock Unitsderivative | -27,778 | $0.00 | $0 | 0 | Dec 15, 2025 |
| Dec 11, 2025 | MOption exercise Restricted Stock Unitsderivative | -30,500 | $0.00 | $0 | 0 | Dec 15, 2025 |
| Dec 11, 2025 | MOption exercise Restricted Stock Unitsderivative | -15,496 | $0.00 | $0 | 0 | Dec 15, 2025 |
| Dec 15, 2025 | CConversion Series C Preferred Stockderivativeindirect: By Goldman-Valeriote Family Trust | -53,732 | - | - | 0 | Dec 15, 2025 |
Related signals
Other insiders at WEALTHFRONT CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | WEALTHFRONT CORP | David Fortunato CEO and President | $1.0M 100,000 shares | -5% | |
| 28Weak | WEALTHFRONT CORP | Kal Iyer VP, Engineering | $270k 26,738 shares | -10% | |
| 44Moderate | WEALTHFRONT CORP | Alan Imberman CFO and Treasurer | $773k 76,540 shares | -16% | |
| 16Weak | WEALTHFRONT CORP | Lauren Lin CLO, CCO and Secretary | $46k 4,574 shares | -3% | |
| 23Weak | WEALTHFRONT CORP | Julien Wetterwald Chief Technology Officer | $264k 26,138 shares | -4% | |
| 50Moderate | WEALTHFRONT CORP | David Fortunato CEO and President | $1.3M 122,203 shares | -6% | |
| 37Weak | WEALTHFRONT CORP | Kal Iyer VP, Engineering | $466k 43,991 shares | -15% | |
| 36Weak | WEALTHFRONT CORP | Alan Imberman CFO and Treasurer | $282k 26,596 shares | -5% | |
| 32Weak | WEALTHFRONT CORP | Lauren Lin CLO, CCO and Secretary | $224k 21,112 shares | -11% | |
| 0Weak | WEALTHFRONT CORP | L Michelle Wilson director | $6,731 638 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.